About janux therapeutics inc - JANX
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.
JANX At a Glance
Janux Therapeutics, Inc.
10955 Vista Sorrento Parkway
San Diego, California 92130
| Phone | 1-858-751-4493 | Revenue | 10.00M | |
| Industry | Biotechnology | Net Income | -113,625,000.00 | |
| Sector | Health Technology | Employees | 109 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
JANX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 85.514 |
| Price to Book Ratio | 0.871 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.574 |
| Enterprise Value to Sales | -8.928 |
| Total Debt to Enterprise Value | -0.248 |
JANX Efficiency
| Revenue/Employee | 91,743.119 |
| Income Per Employee | -1,042,431.193 |
| Receivables Turnover | 1.556 |
| Total Asset Turnover | 0.01 |
JANX Liquidity
| Current Ratio | 39.04 |
| Quick Ratio | 39.04 |
| Cash Ratio | 38.667 |
JANX Profitability
| Gross Margin | 79.71 |
| Operating Margin | -1,576.67 |
| Pretax Margin | -1,136.25 |
| Net Margin | -1,136.25 |
| Return on Assets | -10.983 |
| Return on Equity | -11.48 |
| Return on Total Capital | -11.607 |
| Return on Invested Capital | -11.247 |
JANX Capital Structure
| Total Debt to Total Equity | 2.314 |
| Total Debt to Total Capital | 2.261 |
| Total Debt to Total Assets | 2.197 |
| Long-Term Debt to Equity | 2.064 |
| Long-Term Debt to Total Capital | 2.017 |